These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
113 related items for PubMed ID: 4762187
1. Inconsistencies in rationale underlying official USP dissolution rate specifications for nitrofurantoin. Bates TR, Rosenberg HA, Tembo AV. J Pharm Sci; 1973 Dec; 62(12):2057-8. PubMed ID: 4762187 [No Abstract] [Full Text] [Related]
2. pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules. Bates TR, Young JM, Wu CM, Rosenberg HA. J Pharm Sci; 1974 Apr; 63(4):643-5. PubMed ID: 4828728 [No Abstract] [Full Text] [Related]
3. Dissolution test acceptance sampling plans. Tsong Y, Hammerstrom T, Lin K, Ong TE. J Biopharm Stat; 1995 Jul; 5(2):171-83. PubMed ID: 7581426 [Abstract] [Full Text] [Related]
4. [Biologic availability of various formulas of nitrofurantoin in tablets]. Frigerio G, Venier A. Boll Chim Farm; 1973 Jul; 112(6):416-21. PubMed ID: 4767643 [No Abstract] [Full Text] [Related]
5. Proceedings: The comparison of the bioavailabilities of commercial nitrofurantoin tablets. McGilveray IJ, Mattok GL, Hossie RD. Rev Can Biol; 1973 Jul; 32():Suppl:99-106. PubMed ID: 4777608 [No Abstract] [Full Text] [Related]
6. Collaborative study of the USP dissolution test for prednisone tablets with Apparatus 2. Cox DC, Furman WB. J Pharm Sci; 1984 May; 73(5):670-6. PubMed ID: 6737242 [Abstract] [Full Text] [Related]
7. Bioavailability of 14 nitrofurantoin products. Meyer MC, Slywka GW, Dann RE, Whyatt PL. J Pharm Sci; 1974 Nov; 63(11):1693-8. PubMed ID: 4427226 [No Abstract] [Full Text] [Related]
8. [In vitro and in vivo investigations with different nitrofurantoin formulations (author's transl)]. Gladigau V, Gebhardt U. Arzneimittelforschung; 1978 Nov; 28(10):1771-8. PubMed ID: 582682 [Abstract] [Full Text] [Related]
13. Systematic error associated with apparatus 2 of the USP dissolution test III: limitations of calibrators and the USP suitability test. Cox DC, Furman WB, Thornton LK, Moore TW, Jefferson EH. J Pharm Sci; 1983 Aug; 72(8):910-3. PubMed ID: 6620145 [Abstract] [Full Text] [Related]
14. A comparative study of BP and USP rotating basket dissolution apparatus. Smith WJ, Heaume PE, Hailey DM, Lea AR. J Pharm Pharmacol; 1985 Feb; 37(2):124-5. PubMed ID: 2858545 [Abstract] [Full Text] [Related]
16. Letter: Utility of preparations of nitrofurantoin. N Engl J Med; 1974 Jun 20; 290(25):1436-7. PubMed ID: 4829566 [No Abstract] [Full Text] [Related]
17. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E, Prakongpan S, Amidon GL, Dressman JB. Clin Pharmacokinet; 2006 Jun 20; 45(4):385-99. PubMed ID: 16584285 [Abstract] [Full Text] [Related]
19. A study of bioavailabilities and dissolution rates of commercial tablets of nitrofurantoin. McGilveray IJ, Mattok GL, Hossie RD. J Pharm Pharmacol; 1971 Dec 20; 23():246S. PubMed ID: 4401504 [No Abstract] [Full Text] [Related]
20. Effect of batch age on potency and dissolution of levothyroxine sodium tablets: impact of BP and USP monograph differences on dissolution results. Abou-Taleb BA, Nounou MI, Khalafallah N, Khalil S. Drug Dev Ind Pharm; 2018 Nov 20; 44(11):1762-1769. PubMed ID: 29973090 [Abstract] [Full Text] [Related] Page: [Next] [New Search]